Book a Demo
Platform Overview
Operations
Operational Impact Deployment & Security Integrations Core Lab Solutions EHR Mining Partnerships
Cardiac Amyloidosis Heart Failure Aortic Stenosis Pulmonary Hypertension Strain Stress Echocardiography
Clinical Evidence Case Studies Testimonials Peer Comparison Authors & Collaborators
News Events ROI Calculator Reimbursements Regulatory Status Evaluating AI Echo Glossary
Our Story Careers Media Kit Patents Trust Center

Your AI Echo Copilot™

AI Echocardiography, From First Frame to Final Report

Every study analyzed automatically — measurements, findings and disease detection, returned as one complete, guideline-based report.

FDA 510(k) Cleared
CE Marked (Class IIb)
HIPAA & GDPR
Book a Demo See the evidence
app.us2.ai/report/echo-analysis

One routine echo study 6 clinical applications

FDA cleared and CE marked. Cleared indications vary by market — confirm for your country.

Scope

Not One Measurement. The Whole Report.

Most AI echo tools assist with a single task — strain, or ejection fraction, or view classification. Us2.ai returns the end-to-end report in one zero-click pass: guideline measurements, diastolic and valvular assessment, and disease detection.

And it runs on the scanners you already own — vendor-neutral across GE, Philips, Siemens, Canon and handheld POCUS.

See what a full report contains
  • Guideline measurements
  • Diastolic function
  • Valvular assessment
  • Chamber quantification
  • Strain (GLS)
  • Disease detection
First-of-its-Kind

AI-Powered Cardiac Amyloidosis Detection

Cardiac amyloidosis is one of the most under-diagnosed conditions in cardiology. Us2.ai is the first platform to combine deep learning pattern recognition with guideline-based echocardiographic measurements for automated detection. FDA cleared and CE marked.

Learn more about our approach →
Pattern Recognition Deep learning applied to standard apical four-chamber view
Guideline-Based Combines AI pattern detection with established measurement criteria
Regulatory Cleared FDA 510(k) cleared and CE marked for clinical use

FDA cleared and CE marked. Cleared indications vary by market — confirm the status for your country.

Proven Results

Measurable Impact, Backed by Evidence

Peer-reviewed studies and clinical deployments show significant efficiency gains across echo labs.

70%
Reduction in reporting time
Read the peer-reviewed reporting-time study →
~75%
Faster diagnosis time
See the clinical deployment diagnosis-time results →
+2
Echo exams per sonographer, per day
View the randomized controlled trial on scan volume →
35–40 → 10
min / study

University of Medicine & Pharmacy Hospital, HCMC: “AI can significantly shorten the diagnosis time… reduce the workload for medical staff, limit errors as well as save treatment costs.”

Le Minh Khoi, Assoc. Prof. & Head of Cardiovascular Imaging
In Their Words
“Well, AI will not replace a physician, but a physician using AI will replace a physician not using AI!”
Wojciech Mazur, MD Director of Advanced Cardiac Imaging, The Christ Hospital Health Network Read the interview
Testimonials

Trusted by Healthcare Professionals Worldwide

Marianna Fontana, MD, PhD
Professor of Cardiology and Honorary Consultant Cardiologist, National Amyloidosis Centre, University College London
Cardiac amyloidosis remains a frequently under-diagnosed condition with significant prognostic implications. Us2.ai's AI-based pattern recognition model, applied to a standard apical four-chamber view, provides a validated and scalable solution to support early detection and enhance clinical decision-making within routine echocardiographic practice.
Jeremy Slivnick, MD
Assistant Professor, Division of Cardiovascular Medicine, The University of Chicago Medicine
Us2.ai's platform already provides powerful automated measurements that support the detection of cardiac amyloidosis. But this new deep learning approach moves beyond standard measurement workflows by enabling fast, fully automated detection of amyloidosis from a single echo view. By simplifying image requirements while maintaining diagnostic accuracy, it has the potential to expand the role of echocardiography as an accessible, practical screening tool for earlier identification of patients with this life threatening yet treatable disease.
Becky Schwaegler, BS, RDMS, RDCS (AE,PE), FASE
Cardiac Sonographer Specialist / Lead
From my personal experience, I have felt very fortunate to be able to use Us2.ai, a remarkable platform... I am truly amazed with its speed, overall accuracy and ease.
Ilya Karagodin, MD
General and Advanced Imaging Cardiologist and Director of AI and Advanced Analytics, Endeavor Health, USA
What we found is that the AI workflow saves, on average, 10 to 12 minutes per study, for a total savings of about 33% per study, which was pretty remarkable.
Nobuyuki Kagiyama, MD, PhD
Associate Professor, Dept. of Cardiovascular Biology and Medicine, Juntendo University
AI provides a consistent 'gold standard' that can be uniformly applied to all examinations, significantly reducing variability between sonographers.
Deepak Borde, MD, DNB, FCA, FTEE
Cardiac Anesthesiologist, United CIIGMA Hospital, India
I can't take my eyes off those images, and I can't believe I could get them with ZERO CLICKS!
Le Minh Khoi, MD
Associate Professor, Head of the Cardiovascular Imaging Unit, University of Medicine and Pharmacy Hospital, Ho Chi Minh City
AI can significantly shorten diagnosis time from 35 to 40 minutes down to about 10 minutes. This innovation not only eases the workload for medical staff but also minimizes errors and reduces treatment costs.
Rudolf de Boer, MD, PhD
Head of the Cardiology Department, Erasmus MC
Thanks to the AI analysis, we immediately receive objective measurements, allowing us to make decisions faster and more consistently. That is a win-win for both the patient and the healthcare provider.
Jacco Karper, MD
Cardiologist, Wilhelmina Ziekenhuis Assen
AI supports the process, but never replaces the medical judgement of the healthcare professional.
Gerrie Venema
Ultrasound Technician, Wilhelmina Ziekenhuis Assen
You should see it as a system that thinks alongside us and supports us in speeding up the analysis.
Sreekanth Vemulapalli, MD
Associate Professor of Medicine, Duke University
The US2 software could enable the use of echocardiography in screening or as a procedure at an accelerated pace and in a cost-effective manner.
Chris Mansi, MD, MBA
CEO, Viz.ai
We are proud to partner with Us2.ai to enhance and complement our comprehensive AI platform, tailoring it to cardiovascular needs, so that cardiologists and care teams can provide optimal care to more patients most efficiently.
Elad Walach
CEO, Aidoc
Our partnership with Us2.ai allows our health system partners to further expand the clinical value of AI to cardiac care. Health systems cannot work with thousands of AI point solutions for each service line. Our aiOS allows health systems to think strategically about AI and build an end-to-end intelligence layer across the health system.
Daniel Cehic, MBBS, MBA, FICOS, FCSANZ, FRACP
CMO, Advara HeartCare
David O'Donnell, MBBS, FRACP, FCSANZ
CEO, Advara HeartCare
At Advara HeartCare we are committed to improving Australia's Heart Health. Whilst our clinical teams remain the focus (or at the heart) of our patients' care, partnering with US2Ai we are excited to investigate how AI can enhance our diagnostic capabilities and optimize the experience and clinical outcomes for our patients.
Read all testimonials
Who It's For

Built for Everyone Who Touches an Echo

Six roles, one automated report. Pick the one that sounds like your week.

How It Works

From Echo Scan to Structured Report, Automatically

Us2.ai connects to your ultrasound devices and PACS, processes echocardiograms (cardiac ultrasound studies) in real time, and delivers standardized, clinician-ready reports.

Us2.ai automated measurements overlaid on an echocardiogram

Zero-Click Analysis

No frame selection, no manual annotations. Studies are processed automatically from DICOM upload to final report. No additional clicks required.

A structured echo report generated by Us2.ai, open in the report editor

Real-Time Processing

Results are ready before the patient leaves the exam room. Automated measurements and disease detection delivered in seconds, not minutes.

Us2.ai guideline-referenced findings inside the reporting workflow

Fits Your Infrastructure

Cloud or on-premise. Connects to any ultrasound device, PACS, CVIS, or EMR. Deploy without changing your existing clinical workflow.

See Full Platform Overview
Published Evidence

67 Indexed Publications, 30 Journals

Every one indexed and individually linked — including Nature Communications, The Lancet Digital Health, the European Heart Journal, JACC, Circulation, and the Journal of the American Society of Echocardiography.

JASE

Browse all 67 publications

Partners

Us2.ai works with healthcare technology partners and academic medical centers including Fujifilm, GE HealthCare, Canon Medical Systems, Microsoft, Viz.ai, Merge, Duke University, and Brigham and Women's Hospital.

See all partnerships
Availability

Where We Operate, and How It Gets Paid For

28

countries with Us2.ai partners and research collaborations

See our partners
CPT & DRG

US reimbursement is in place today — CPT for outpatient, DRG for inpatient. Coverage and codes differ everywhere else.

Reimbursement in your market
ROI

Model the payback for your own lab — study volume, staffing and reporting time.

Estimate your ROI
FDA · CE

Cleared indications and regulatory status differ by market.

Check your market
Deployment

From Kickoff to Go-Live in About a Month

Cloud or on‑premise. Works with your existing PACS, CVIS, and EMR via standard DICOM routing. No rip-and-replace.

  1. 1

    Scoping

    Week 1–2

    Review infrastructure, DICOM routing, and integration points.

  2. 2

    Install

    Week 2–3

    Provision cloud instance or deploy on-premise server. Configure DICOM.

  3. 3

    Validate

    Week 3–4

    Run test studies; confirm PACS/CVIS/EMR integration end-to-end.

  4. 4

    Go Live

    Week 4+

    Production routing, ongoing monitoring, support. Disable any time.

Cloud Managed hosting. No on-site hardware. Automatic updates and scaling.
On‑premise Dedicated hardware in your data center. Air-gap compatible. IT retains control.
See deployment & security details
Trust & Security

Enterprise-Grade Security and Compliance

GDPR & HIPAA Compliant

Protecting patient data with global privacy standards

ISO 27001:2022 Certified

Industry-leading information security practices

SOC 2 Type II

Proven security controls to keep your data safe

MDSAP Certified

Ensuring medical device safety and regulatory compliance

Deployment & security detail Book a Demo

Visit Trust Center

FAQ

Frequently Asked Questions

Quick answers to what buyers and clinicians ask first. For deeper product detail, see the platform overview.

What does Us2.ai do?
Us2.ai is an FDA-cleared AI platform that fully automates echocardiogram analysis: measurements, disease detection, and a structured report generated in seconds from a single DICOM upload. It plugs into existing PACS, CVIS, and reporting systems without changing how studies are acquired.
How is Us2.ai different from other AI echocardiography tools?
Three differences a buyer can verify. Breadth of indication: cardiac amyloidosis, heart failure, aortic stenosis and pulmonary hypertension are screened in the same pass that produces the report, and Us2.ai is the first echo AI cleared for cardiac amyloidosis detection. Depth of evidence: the results are published in peer-reviewed journals and indexed here paper by paper, rather than summarized. Independence: it is vendor-neutral across GE, Philips, Siemens, Canon and handheld POCUS, and deploys cloud or on-premise.
Is echocardiography the same as cardiac ultrasound?
Yes. Echocardiography is ultrasound imaging of the heart, and an echocardiogram is a cardiac ultrasound scan. Us2.ai brings AI to cardiac ultrasound (echocardiography) specifically: it reads standard echo loops and generates a full structured report in seconds. Its FDA and CE clearances cover echocardiography, not general-purpose ultrasound of other organs.
Where is Us2.ai cleared for clinical use?
Us2.ai holds regulatory clearance in 28+ markets including FDA (US), CE MDR (EU), MHRA (UK), TGA (Australia), Health Canada, PMDA (Japan), and HSA (Singapore). See Regulatory Status for the full market-by-market list with certificate identifiers.
How long does it take to deploy Us2.ai?
Typical go-live is about one month from kickoff: scoping, install, clinical validation, and production. Cloud deployments are fastest; on-premise installations follow the same four milestones with hospital-IT involvement during install. See Deployment & Security for the full implementation playbook.
Is AI echocardiography reimbursable?
In the US, echocardiography procedures are billed under established Category I CPT codes (e.g. 93306 for complete TTE, 93350 for stress echo). For specific AI-enabled coded indications, CMS has established dedicated codes, for example Category III code 0932T for AI-derived heart failure with preserved ejection fraction (HFpEF) detection, effective January 1, 2025. See US Reimbursement for codes, Medicare payment methodologies, and OPPS / NTAP detail. Per-country coding and coverage for 12 other markets plus a 9-market bundle is available under Reimbursement worldwide.
How accurate is Us2.ai?
Us2.ai’s automated measurements have been validated in peer-reviewed studies against expert readers, with agreement at or above inter-reader variability for ejection fraction, GLS, diastolic function, and disease detection endpoints. See Clinical Evidence for the full publication record.
Is patient data safe with Us2.ai?
Yes. Us2.ai is HIPAA and GDPR compliant, ISO 27001:2022 certified, SOC 2 Type II audited, and MDSAP certified. On-premise deployment is available where data must remain inside the hospital network.
Get Started

Book a Demo

Message Sent!

Thank you for reaching out. Our team will review your message and get back to you within 1-2 business days.

72 Circular Road, #03-01, Singapore 049426
+65 6232 7857
[email protected]